Literature DB >> 11916281

Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma.

Douglas Van Nostrand1, Frank Atkins, Fred Yeganeh, Elmo Acio, Randy Bursaw, Leonard Wartofsky.   

Abstract

In the absence of definitive studies relating radioiodine dose to outcomes, selection of a dose of radioiodine to treat metastatic thyroid carcinoma is problematic, and several approaches have been used. These include empiric fixed doses and doses used on dosimetric approaches specific for each patient. This paper is a review of the rationale and technique for dosimetrically-determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. This review (1) discusses the alternatives for selection of a dose, (2) discusses the two major approaches for determining radioiodine doses dosimetrically, (3) briefly reviews several modifications of these approaches, (4) reviews the literature regarding the results, (5) discusses the side effects of these different approaches, and (6) concludes with recommendations for patient management and future research. This review does not address use of dosimetrically-determined doses of radioiodine for the initial ablation of thyroid tissue postoperatively.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11916281     DOI： 10.1089/105072502753522356

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


  22 in total

Review 1.  Radioiodine treatment of well-differentiated thyroid cancer.

Authors:  Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

2.  Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?

Authors:  Massimo Salvatori; Germano Perotti; Luca Giovanella; Massimo Eugenio Dottorini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

3.  Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Thyroid       Date:  2012-02-07       Impact factor: 6.568

4.  Effects of Dosimetrically Guided I-131 Therapy on Hematopoiesis in Patients With Differentiated Thyroid Cancer.

Authors:  Athanasios Bikas; Mark Schneider; Sameer Desale; Frank Atkins; Mihriye Mete; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  J Clin Endocrinol Metab       Date:  2016-02-22       Impact factor: 5.958

Review 5.  Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.

Authors:  George Sgouros; Robert F Hobbs; Francis B Atkins; Douglas Van Nostrand; Paul W Ladenson; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

Authors:  F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti
Journal:  J Endocrinol Invest       Date:  2018-05-04       Impact factor: 4.256

8.  Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.

Authors:  Sarah Urnauer; Stephan Morys; Ana Krhac Levacic; Andrea M Müller; Christina Schug; Kathrin A Schmohl; Nathalie Schwenk; Christian Zach; Janette Carlsen; Peter Bartenstein; Ernst Wagner; Christine Spitzweg
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

Review 9.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

10.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.

Authors:  Michael Lassmann; Heribert Hänscheid; Carlo Chiesa; Cecilia Hindorf; Glenn Flux; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.